# Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

> **NCT00020761** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 51 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00020761
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2002-12
- **Final completion:** 2005-08
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00020761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00020761, "Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00020761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*